Cargando…

Recent advances in the treatment of juvenile idiopathic arthritis–associated uveitis

Juvenile idiopathic arthritis–associated uveitis has an estimated prevalence of 10–20% in patients with juvenile idiopathic arthritis, making it the most common cause of chronic anterior uveitis in children. Prompt treatment is important to prevent development of ocular complications and permanent v...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Judy L., Abiri, Parinaz, Tsui, Edmund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897841/
https://www.ncbi.nlm.nih.gov/pubmed/33681703
http://dx.doi.org/10.1177/2515841420984572
_version_ 1783653750140829696
author Chen, Judy L.
Abiri, Parinaz
Tsui, Edmund
author_facet Chen, Judy L.
Abiri, Parinaz
Tsui, Edmund
author_sort Chen, Judy L.
collection PubMed
description Juvenile idiopathic arthritis–associated uveitis has an estimated prevalence of 10–20% in patients with juvenile idiopathic arthritis, making it the most common cause of chronic anterior uveitis in children. Prompt treatment is important to prevent development of ocular complications and permanent vision loss. In this review, we will discuss the use of immunosuppression in treatment of juvenile idiopathic arthritis–associated uveitis. This will include the use of conventional immunosuppressants, such as methotrexate, biologic anti-tumor necrosis factor agents, such as adalimumab, as well as other anti-tumor necrosis factor agents, including infliximab and golimumab. In addition, we will discuss medications currently in clinical trials or under consideration for juvenile idiopathic arthritis–associated uveitis, including interleukin-6 inhibitors (tocilizumab) and Janus kinase inhibitors (tofacitinib, baricitinib).
format Online
Article
Text
id pubmed-7897841
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-78978412021-03-04 Recent advances in the treatment of juvenile idiopathic arthritis–associated uveitis Chen, Judy L. Abiri, Parinaz Tsui, Edmund Ther Adv Ophthalmol Ophthalmic Manifestations of Paediatric Systemic Diseases Juvenile idiopathic arthritis–associated uveitis has an estimated prevalence of 10–20% in patients with juvenile idiopathic arthritis, making it the most common cause of chronic anterior uveitis in children. Prompt treatment is important to prevent development of ocular complications and permanent vision loss. In this review, we will discuss the use of immunosuppression in treatment of juvenile idiopathic arthritis–associated uveitis. This will include the use of conventional immunosuppressants, such as methotrexate, biologic anti-tumor necrosis factor agents, such as adalimumab, as well as other anti-tumor necrosis factor agents, including infliximab and golimumab. In addition, we will discuss medications currently in clinical trials or under consideration for juvenile idiopathic arthritis–associated uveitis, including interleukin-6 inhibitors (tocilizumab) and Janus kinase inhibitors (tofacitinib, baricitinib). SAGE Publications 2021-02-18 /pmc/articles/PMC7897841/ /pubmed/33681703 http://dx.doi.org/10.1177/2515841420984572 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Ophthalmic Manifestations of Paediatric Systemic Diseases
Chen, Judy L.
Abiri, Parinaz
Tsui, Edmund
Recent advances in the treatment of juvenile idiopathic arthritis–associated uveitis
title Recent advances in the treatment of juvenile idiopathic arthritis–associated uveitis
title_full Recent advances in the treatment of juvenile idiopathic arthritis–associated uveitis
title_fullStr Recent advances in the treatment of juvenile idiopathic arthritis–associated uveitis
title_full_unstemmed Recent advances in the treatment of juvenile idiopathic arthritis–associated uveitis
title_short Recent advances in the treatment of juvenile idiopathic arthritis–associated uveitis
title_sort recent advances in the treatment of juvenile idiopathic arthritis–associated uveitis
topic Ophthalmic Manifestations of Paediatric Systemic Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897841/
https://www.ncbi.nlm.nih.gov/pubmed/33681703
http://dx.doi.org/10.1177/2515841420984572
work_keys_str_mv AT chenjudyl recentadvancesinthetreatmentofjuvenileidiopathicarthritisassociateduveitis
AT abiriparinaz recentadvancesinthetreatmentofjuvenileidiopathicarthritisassociateduveitis
AT tsuiedmund recentadvancesinthetreatmentofjuvenileidiopathicarthritisassociateduveitis